Loading...
•
Sep 30, 2021
Cardiff Oncology Q3 2021 Earnings Report
Cardiff Oncology's third quarter results for 2021 were reported, along with business updates, including clinical data from the KRAS-mutated metastatic colorectal cancer program and appointments of a CMO and CFO.
Key Takeaways
Cardiff Oncology reported third quarter results, highlighting positive clinical data from its KRAS-mutated metastatic colorectal cancer program and the appointments of a new CMO and CFO. The company had $134 million in cash, cash equivalents, and short-term investments as of September 30, 2021. Total operating expenses were $7.1 million for the quarter, with increases in research and development, and selling, general and administrative expenses.
Announced updated clinical data from lead KRAS-mutated metastatic colorectal cancer program showing an objective response rate and median progression free survival that substantially exceed those seen in historical control trials.
Strengthened management team with the appointments of Katherine L. Ruffner, M.D., as CMO and James E. Levine as CFO
Cash, cash equivalents, and short-term investments of approximately $134 million as of September 30, 2021
Total operating expenses were approximately $7.1 million for the three months ended September 30, 2021, an increase of $2.6 million from $4.5 million for the same period in 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...